Kaleido Biosciences, Inc. (KLDO)
KLDO Stock Price Chart
Explore Kaleido Biosciences, Inc. interactive price chart. Choose custom timeframes to analyze KLDO price movements and trends.
KLDO Company Profile
Discover essential business fundamentals and corporate details for Kaleido Biosciences, Inc. (KLDO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
28 Feb 2019
Employees
76.00
Website
https://kaleido.comCEO
Mark A. Wingertzahn
Description
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
KLDO Financial Timeline
Browse a chronological timeline of Kaleido Biosciences, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 22 May 2023
Earnings released on 27 Mar 2023
Earnings released on 19 Dec 2022
Earnings released on 1 Apr 2022
EPS came in at -$0.47 surpassing the estimated -$0.58 by +18.97%.
Earnings released on 31 Dec 2021
EPS came in at -$0.00 , while revenue for the quarter reached $492.00K .
Earnings released on 1 Nov 2021
EPS came in at -$0.54 matching the estimated -$0.54, while revenue for the quarter reached $104.00K , missing expectations by -38.82%.
Earnings released on 11 Aug 2021
EPS came in at -$0.56 surpassing the estimated -$0.57 by +1.75%, while revenue for the quarter reached $211.00K , beating expectations by +91.82%.
Earnings released on 4 May 2021
EPS came in at -$0.58 surpassing the estimated -$0.59 by +1.69%, while revenue for the quarter reached $297.00K , missing expectations by -1.67%.
Earnings released on 3 Mar 2021
EPS came in at -$0.56 falling short of the estimated -$0.40 by -40.00%, while revenue for the quarter reached $243.00K , missing expectations by -97.84%.
Earnings released on 2 Nov 2020
EPS came in at -$0.65 falling short of the estimated -$0.63 by -3.17%, while revenue for the quarter reached $482.00K , missing expectations by -32.06%.
KLDO Stock Performance
Access detailed KLDO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.